Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
Gold Price Trend Forecast into 2021, Is Intel Dying?, Can Trump Win 2020? - 20th Oct 20
Gold Asks Where Is The Inflation - 20th Oct 20
Last Chance for this FREE Online Trading Course Worth $129 value - 20th Oct 20
More Short-term Stock Market Weakness Ahead - 20th Oct 20
Dell S3220DGF 32 Inch Curved Gaming Monitor Unboxing and Stand Assembly and Range of Movement - 20th Oct 20
Best Retail POS Software In Australia - 20th Oct 20
From Recession to an Ever-Deeper One - 19th Oct 20
Wales Closes Border With England, Stranded Motorists on Severn Bridge? Covid-19 Police Road Blocks - 19th Oct 20
Commodity Bull Market Cycle Starts with Euro and Dollar Trend Changes - 19th Oct 20
Stock Market Melt-Up Triggered a Short Squeeze In The NASDAQ and a Utilities Breakout - 19th Oct 20
Silver is Like Gold on Steroids - 19th Oct 20
Countdown to Election Mediocrity: Why Gold and Silver Can Protect Your Wealth - 19th Oct 20
“Hypergrowth” Is Spilling Into the Stock Market Like Never Before - 19th Oct 20
Is Oculus Quest 2 Good Upgrade for Samsung Gear VR Users? - 19th Oct 20
Low US Dollar Risky for Gold - 17th Oct 20
US 2020 Election: Are American's ready for Trump 2nd Term Twilight Zone Presidency? - 17th Oct 20
Custom Ryzen 5950x, 5900x, 5800x , RTX 3080, 3070 64gb DDR4 Gaming PC System Build Specs - 17th Oct 20
Gold Jumps above $1,900 Again - 16th Oct 20
US Economic Recovery Is in Need of Some Rescue - 16th Oct 20
Why You Should Focus on Growth Stocks Today - 16th Oct 20
Why Now is BEST Time to Upgrade Your PC System for Years - Ryzen 5000 CPUs, Nvidia RTX 3000 GPU's - 16th Oct 20
Beware of Trump’s October (November?) Election Surprise - 15th Oct 20
Stock Market SPY Retesting Critical Resistance From Fibonacci Price Amplitude Arc - 15th Oct 20
Fed Chairman Begs Congress to Stimulate Beleaguered US Economy - 15th Oct 20
Is Gold Market Going Back Into the 1970s? - 15th Oct 20
Things you Should know before Trade Cryptos - 15th Oct 20
Gold and Silver Price Ready For Another Rally Attempt - 14th Oct 20
Do Low Interest Rates Mean Higher Stocks? Not so Fast… - 14th Oct 20
US Debt Is Going Up but Leaving GDP Behind - 14th Oct 20
Dell S3220DGF 31.5 Inch VA Gaming Monitor Amazon Prime Day Bargain Price! But WIll it Get Delivered? - 14th Oct 20
Karcher K7 Pressure Washer Amazon Prime Day Bargain 51% Discount! - 14th Oct 20
Top Strategies Day Traders Adopt - 14th Oct 20
AMD is KILLING Intel as Ryzen Zen 3 Takes Gaming Crown, AMD Set to Achieve CPU Market Dominance - 13th Oct 20
Amazon Prime Day Real or Fake Sales to Get Rid of Dead Stock? - 13th Oct 20
Stock Market Short-term Top Expected - 13th Oct 20
Fun Stuff to Do with a Budgie or Parakeet, a Child's Best Pet Bird Friend - 13th Oct 20
Who Will Win the Race to Open a Casino in Japan? - 13th Oct 20
Fear Grips Stock Market Short-Sellers -- What to Make of It - 12th Oct 20
For Some Remote Workers, It Pays to Stay Home… If Home Stays Local - 12th Oct 20
A Big Move In Silver: Watch The Currency Markets - 12th Oct 20
Precious Metals and Commodities Comprehensive - 11th Oct 20
The Election Does Not Matter, Stick With Stock Winners Like Clean Energy - 11th Oct 20
Gold Stocks Are Cheap, But Not for Long - 11th Oct 20
Gold Miners Ready to Fall Further - 10th Oct 29
What Happens When the Stumble-Through Economy Stalls - 10th Oct 29
This Is What The Stock Market Is Saying About Trump’s Re-Election - 10th Oct 29
Here Is Everything You Must Know About Insolvency - 10th Oct 29
Sheffield Coronavirus Warning - UK Heading for Higher Covid-19 Infections than April Peak! - 10th Oct 29
Q2 Was Disastrous. But What’s Next for the US Economy – and Gold? - 9th Oct 20
Q4 Market Forecast: How to Invest in a World Awash in Debt - 9th Oct 20
A complete paradigm shift will make gold the generational trade - 9th Oct 20
Why You Should Look for Stocks Climbing Out of a “Big Base” - 9th Oct 20
UK Coronavirus Pandemic Wave 2 - Daily Covid-19 Positive Test Cases Forecast - 9th Oct 20
Ryzen ZEN 3: The Final Nail in Intel's Coffin! Cinebench Scores 5300x, 5600x, 5800x, 5900x 5950x - 9th Oct 20

Market Oracle FREE Newsletter

How to Get Rich Investing in Stocks by Riding the Electron Wave

Healing the Blind… and Boosting Your Stocks Portfolio

Companies / BioTech May 24, 2014 - 01:38 PM GMT

By: Casey_Research

Companies

By Chris Wood, Senior Analyst

Vision is one of the most important elements of our life, if not the most important one. A 2010 survey by Surge Research found that 60% of Americans are more afraid of blindness than of heart disease, the primary killer of both men and women in the United States.


For a massive 79% of the surveyed, other than their own death or the death of a loved one, losing their eyesight is “the worst thing that could happen to me.”

Unfortunately, this is a scenario that is all too real for a growing number of people, due to macular degeneration, a progressive eye condition that affects as many as 16 million people in the US and millions more around the world.

The fastest-growing form of the disease is age-related macular degeneration, or AMD. It is the number-one cause of severe vision loss and legal blindness in adults over 60 in the United States; and as baby boomers advance into their sixties and seventies, we will see a virtual epidemic of the disease.

Current estimates show that AMD affects between 14% and 24% of the US population aged 65 to 74 years and as much as 35% of people over 75.

AMD itself can be separated into two types: the wet form and the dry form. Wet AMD is the more severe type of the disease; and while only 10% of AMD patients suffer from it, it accounts for 90% of the severe vision loss caused by macular degeneration.

According to the NIH's National Eye Institute, more than 1.6 million Americans suffer from wet AMD—a figure that’s expected to climb to just under 3 million by 2020.

Wet AMD involves the growth of an abnormal bundle of blood vessels (called a “lesion”) behind the macula, the central part of the retina at the back of the eye that allows us to see fine details clearly. When the macula doesn’t function correctly, we experience blurriness or darkness in the center of our vision. In wet AMD, the abnormal blood vessels that have grown behind the macula tend to be very fragile and often leak blood and fluid into the region, raising the macula from its normal place and distorting vision.

There’s No Cure, and Current Therapies All Suffer from the Same Drawbacks

Today, the condition is treated primarily with one of three macromolecular drugs: Lucentis, Eylea, and off-label Avastin. All of them work by directly inhibiting vascular endothelial growth factor (VEGF), and all of them have been shown to be essentially clinically equivalent (meaning each of them works as well as the others).

Annual worldwide revenue for Lucentis and Eylea is about $5.3 billion, though off-label use of the much cheaper Avastin (estimated at 60% by volume) has severely eaten into their market share. This global market is expected to grow to $8.2 billion by 2016.

The current treatments are somewhat effective, but they only address part of the problem. According to Dr. Peter Kaiser, the editor-in-chief of the Retinal Physician journal and one of the thought leaders in the industry:

“For the past 7 years, we focused our attention on blocking VEGF in order to reduce angiogenesis in wet-AMD patients. But as more and more data appeared, it seemed that the VEGF inhibitors largely worked by reducing the leakage, not by eliminating choroidal neovascularization. It is this neovascularization, otherwise known as the lesion, that causes the leakiness. Therefore, we have been patching leaks all these years and not fixing the problem.”

What's more, a substantial number of patients with wet AMD do not respond well to anti-VEGF treatment, and more than 10% of patients don’t respond at all. Plus, the therapy, which involves frequent injections in the eye, holds associated risks such as retinal tear or detachment.

Thus, there's a clear need for a wet-AMD drug that gets to the actual source of the leakiness (i.e., the lesion itself)—and does so with fewer injections at a comparable cost.

Lpath Inc. (LPTN)—Savior from Blindness?

That's where San Diego, California-based Lpath Inc. (LPTN) and its lead drug candidate iSONEP come in. iSONEP is a genetically engineered protein that acts as an antibody against the bioactive lipid called sphingosine-1-phosphate (S1P).

Bioactive lipids in general make for interesting drug targets. S1P in particular is a well-validated target that plays a key role as a signaling mechanism in many pathologic conditions. A growing body of evidence suggests that inhibiting the action of S1P could be an effective therapeutic treatment for wet AMD that may offer distinct advantages over the anti-VEGF drugs currently on the market.

The data so far seems to bear this out. In 2009, Lpath completed a Phase I trial of iSONEP in patients with wet AMD. The results showed that patients tolerated the drug well in various doses, with no serious side effects. It also showed lesion regression in a number of patients.

Of the five patients in the study who had occult-type disease— an earlier-stage wet AMD that affects about 80% of the newly diagnosed patients worldwide—four of them showed a 30%-plus reduction in lesion size from a single injection of iSONEP.

Over the course of the treatment, scientists observed an average 76% reduction in lesion size, with two of the patients showing complete (100%) regression of their lesion. What's more, neither of those patients required any more injections for the entire 12-month follow-up period. (In contrast, Lucentis and Eylea are typically administered once a month and once every other month, respectively.)

Is there risk? Of course. Trying to assess efficacy from a phase I trial always has its dangers—but the limited data we have on iSONEP so far are intriguing. More data are coming soon, too: the results from the Phase II Nexus trial are expected in the second half of 2014.

Positive results from the trial will no doubt send the company’s stock price higher—maybe much higher. If the trial is unsuccessful, however, LPTN could lose much of its value.

This is not a play for the faint of heart, but if you are looking to add to the speculative portion of your portfolio, LPTN might be a great place to start.

To see our full analysis of Lpath Inc. and get our ongoing, up-to-date guidance on this and our other promising stocks, try Casey Extraordinary Technology risk-free today. Right now, we’re offering it for  25% off and with an extended, 6-month money-back guarantee. But hurry, this offer ends on May 26. Click here to get started now.

The article Healing the Blind… and Boosting Your Portfolio was originally published at caseyresearch.com.

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

Casey Research Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules